FDA approval of Akynzeo®

The U.S. Food & Drug Administration approves Helsinn's drug 'Akynzeo' for the prevention of acute and delayed phase nausea and vomiting in patients undergoing cancer chemotherapy.

CHMP Positive Opinion for Akynzeo® in the European Union

European Medicines Agency (EMA) has adopted a positive opinion recommending that Akynzeo®(netupitant-palonosetron),  be granted approval for the prevention of acute and delayed nausea and vomiting in patients undergoing highly emetogenic cisplatin‑based and moderately emetogenic cancer chemotherapy.


Prev Next

April 15, 2015

Decision of the National Comprehensive Cancer Network (NCCN) to include AKYNZEO® in the 2015 ...


April 09, 2015

Helsinn, the Swiss Group focused on building quality cancer care, today announces the publica...


April 02, 2015

Helsinn manufacturing achieved a top 10% score in eight buyer perception categories


March 30, 2015

Helsinn Group Receives Positive CHMP Opinion for Akynzeo® (netupitant/palonosetron) for the P...